Pfizer to Acquire Metsera in $4.9B, Expanding into Obesity and Cardiometabolic Therapies

New York, September 24, 2025 (Business Wire) -- Pfizer announced a definitive agreement to acquire Metsera, a clinical-stage biotech developing therapies for obesity and cardiometabolic diseases, in a cash deal valued at $4.9 billion plus up to $22.50 per share in contingent value rights (CVRs). Metsera’s pipeline includes differentiated oral and injectable incretin and non-incretin candidates, with programs in Phase 1 and 2 trials, including GLP-1 receptor agonists and a monthly amylin analog. The acquisition positions Pfizer to leverage its cardiometabolic expertise and commercial infrastructure to accelerate potential best-in-class treatments for obesity, with the transaction expected to close in Q4 2025 pending regulatory and shareholder approvals.

Read full article here.